oncnursingnews2d
FDA Approves Revumenib for Relapsed, Refractory Acute Leukemia With a KMT2A Translocation
The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...
oncnursingnews3d
Real World CAR T and Bispecific Data May Differ from Trials in DLBCL
Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...
oncnursingnews5d
Topical Drug Combos May Be Beneficial for CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
oncnursingnews5d
Caregivers, Clinicians Must Be Familiar With CRS Risk After CAR T-Cell Therapy
At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...
oncnursingnews2d
Gilda's Club South Jersey
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews2d
Kate Jeffers, PharmD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews3d
Ann Culkin, RN, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
Jackie Herigodt
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...